Search research articles
Contact Us
Filters
Showing results (531-540 of 547) with videos related to
Page
of 55
Sort By:
Immunotherapy Advances
|
August 4, 2023
Establishing a single-sex controlled human <i>Schistosoma mansoni</i> infection model for Uganda: protocol for safety and dose-finding trial
Andrew Abaasa, Moses Egesa, Emmanuella Driciru, et al.
BMC Public Health
|
August 15, 2023
Thetha Nami ngithethe nawe (Let's Talk): a stepped-wedge cluster randomised trial of social mobilisation by peer navigators into community-based sexual health and HIV care, including pre-exposure prophylaxis (PrEP), to reduce sexually transmissible HIV amongst young people in rural KwaZulu-Natal, South Africa
Jacob Busang, Thembelihle Zuma, Carina Herbst, et al.
BMJ Global Health
|
November 10, 2022
Cancer research across Africa: a comparative bibliometric analysis
Miriam Mutebi, Grant Lewison, Ajay Aggarwal, et al.
Journal of Aging and Health
|
January 14, 2025
Longitudinal Trends in Physical Activity Among Older Adults With and Without HIV in Uganda
Aneeka Ratnayake, Yao Tong, Zahra Reynolds, et al.
Ebiomedicine
|
June 16, 2023
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial
Carolina Herrera, Jennifer Serwanga, Laura Else, et al.
Contemporary Clinical Trials
|
January 9, 2026
Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, et al.
The Lancet. HIV
|
April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
Adeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
The Lancet. Global Health
|
June 18, 2021
Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study
Emily B Wong, Stephen Olivier, Resign Gunda, et al.
Journal of Viral Hepatitis
|
May 27, 2024
Peer support for people living with hepatitis B virus-A foundation for treatment expansion
Louise O Downs, Kenneth Kabagambe, Sarah Williams, et al.
The Lancet. Global Health
|
August 17, 2023
The met and unmet health needs for HIV, hypertension, and diabetes in rural KwaZulu-Natal, South Africa: analysis of a cross-sectional multimorbidity survey
Urisha Singh, Stephen Olivier, Diego Cuadros, et al.
Page
of 55
Search research articles
Search
Showing results (531-540 of 547) with videos related to
Sort By:
Page
of 55
Immunotherapy Advances
|
August 4, 2023
Establishing a single-sex controlled human <i>Schistosoma mansoni</i> infection model for Uganda: protocol for safety and dose-finding trial
Andrew Abaasa, Moses Egesa, Emmanuella Driciru, et al.
BMC Public Health
|
August 15, 2023
Thetha Nami ngithethe nawe (Let's Talk): a stepped-wedge cluster randomised trial of social mobilisation by peer navigators into community-based sexual health and HIV care, including pre-exposure prophylaxis (PrEP), to reduce sexually transmissible HIV amongst young people in rural KwaZulu-Natal, South Africa
Jacob Busang, Thembelihle Zuma, Carina Herbst, et al.
BMJ Global Health
|
November 10, 2022
Cancer research across Africa: a comparative bibliometric analysis
Miriam Mutebi, Grant Lewison, Ajay Aggarwal, et al.
Journal of Aging and Health
|
January 14, 2025
Longitudinal Trends in Physical Activity Among Older Adults With and Without HIV in Uganda
Aneeka Ratnayake, Yao Tong, Zahra Reynolds, et al.
Ebiomedicine
|
June 16, 2023
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial
Carolina Herrera, Jennifer Serwanga, Laura Else, et al.
Contemporary Clinical Trials
|
January 9, 2026
Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, et al.
The Lancet. HIV
|
April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
Adeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
The Lancet. Global Health
|
June 18, 2021
Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study
Emily B Wong, Stephen Olivier, Resign Gunda, et al.
Journal of Viral Hepatitis
|
May 27, 2024
Peer support for people living with hepatitis B virus-A foundation for treatment expansion
Louise O Downs, Kenneth Kabagambe, Sarah Williams, et al.
The Lancet. Global Health
|
August 17, 2023
The met and unmet health needs for HIV, hypertension, and diabetes in rural KwaZulu-Natal, South Africa: analysis of a cross-sectional multimorbidity survey
Urisha Singh, Stephen Olivier, Diego Cuadros, et al.
Page
of 55